Please login to the form below

Not currently logged in
Email:
Password:

patritumab

This page shows the latest patritumab news and features for those working in and with pharma, biotech and healthcare.

Daiichi gets breakthrough status for pre-NDA leukaemia drug

Daiichi gets breakthrough status for pre-NDA leukaemia drug

of HER3 inhibitor patritumab in combination with Roche’s EGFR drug Tarceva (erlotinib) in the same indication on disappointing efficacy data. ... Patritumab is still in mid-stage testing for head and neck cancer.

Latest news

  • Daiichi pulls study of patritumab in lung cancer Daiichi pulls study of patritumab in lung cancer

    Daiichi Sankyo has halted a late-stage trial of its HER3 inhibitor patritumab after seeing no evidence of efficacy at an interim analysis. ... This particular result does not directly affect the science of patritumab in other settings," said Yver.

  • Daiichi Sankyo to shut down German antibody unit U3 Daiichi Sankyo to shut down German antibody unit U3

    cancer. U3 Pharma's lead candidate patritumab (U3-1287), an anti-HER3 antibody in clinical trials for non-small cell lung cancer (NSCLC), breast cancer and head and neck cancer, was

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Kardex

Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...